

# FOUNDATION KIND BETER AT THE HAGUE

Annual Report 2022



### **CONTENTS**

		Page
AUDI	TOR'S REPORT	
1 2	Engagement Compilation report	3 3
1	MANAGEMENT REPORT	4
FINA	NCIAL STATEMENTS	
1 2 3	Balance sheet as at December 31, 2022 Profit and loss account over 2022 Notes to the financial statements	7 8 9
4 5	Notes to the balance sheet as of December 31, 2022 Notes to the profit and loss account 2022	10 12





To the management of Foundation Kind Beter Brusselselaan 12 2587 AH The Hague

Reference Processed by Date

19110 WKO June 5, 2023

Dear management,

We hereby send you the report regarding the financial statements for the year 2022 of the foundation.

### 1 ENGAGEMENT

In accordance with your instructions we have compiled the annual account 2022 of the foundation, including the balance sheet with counts of  $\in$  12,120 and the profit and loss account with a negative result of  $\in$  14,186.

### 2 COMPILATION REPORT

### Introduction

In accordance with your instructions we have compiled the financial statements 2022 of Stichting Kind Beter in The Hague, which comprise the balance sheet as at December 31, 2022, the profit and loss account for 2022 and the notes.

Management's responsibility

The distinctive feature of a compilation engagement is that we compile financial information based on information provided by management of the entity. Management is responsible for the accuracy and completeness of the information provided and the financial statements based thereon.

### Confirmation

Based on the information provided to us, we have compiled the financial statements using the accounting policies as included in Part 9 of Book 2 of the Dutch Civil Code.



#### 1 MANAGEMENT REPORT

### Background:

In 2012 our Fenn was born. He seemed like an ordinary boy, but it soon turned out that he has a rare condition. The genetic disorder on the FoxP1 gene has only been known for a short time and no fundamental research has yet been carried out into the cause and a possible solution. More and more cases are now being identified. It is estimated that there are about 250 known cases of this syndrome worldwide. The degree to which this syndrome manifests itself varies from child to child.

A research program has been defined together with the medical university of Leiden (LUMC). Financing had to be arranged for this. Stichting Kind Beter was created to provide for this.

Due to Covid-19, it was difficult to actively recruit for funding. Not only are companies less inclined to donate, we also had more challenges on a personal level due to our son's home education during the lock downs.

Thanks to the action of Tom and Annemiek, Walking in her shoes (walkinginhershoes.nl), we had collected a very nice amount in 2020. In 2021, a number of substantial donations had been received from various capital funds and sufficient funds had been raised for the first year. The LUMC therefore decided to start the research already and in June 2021 the time had come. The research started.

In 2022 we were very successful again in collecting donations. Substantial amounts were raised, especially through several capital funds. The second year therefore started, as planned, on June 1, 2022.

The results are promising, and we certainly expect to continue with research beyond the second year. This is currently being discussed.

In the past year we have not only been busy with fundraising, but we are also becoming more and more a source of information for all FoxP1 parents in the Netherlands. In 2022, partly because of us, a NL FoxP1 day was organized for the first time, where parents and children could meet.

The team around the research is also becoming broader and not only is a clinical geneticist connected, but we are also involved as an organization in the international patient association (foxp1.org).

#### Vision

We believe that, with the right effort, people can be convinced to contribute to a solution for rare diseases.

### Ambition:

A solution for FoxP1 within a period of five to ten years. Due to the delay due to Covid 19, we had to extend this target slightly (from five to five to ten years), but the ambition for a solution remains undiminished.

### Objective:

#### Initially:

Funding research into the cause and possible cure of the rare disease FoxP1 syndrome; Funding possible medical treatment/drugs to cure FoxP1 syndrome.

### In the second instance:

Screening for possible related diseases that may qualify for further analysis through this study.

#### General:

Developing and maintaining relevant relationships to promote the realization of the stated objectives.



Organization and management:

The foundation has no employees. The Board did not change since 2018.

The board does not receive any payment for their activities.

We now also have a few voluntary employees: Sylvia Bos and Annemiek Linn.

They both spent many Sundays in 2022 to work together to raise funds and send out all applications.

#### Finally:

We continue to fight for our ultimate goal: research into FoxP1 with other genetic diseases linked to it. Because every child deserves to get better.

Board of Stichting Kind Beter; Chairman Andre de Koning Secretary Esther Kloosterman Treasurer Wilko Korving



# **FINANCIAL STATEMENTS**







**ASSETS** 

**Current assets** 

## Stichting Kind Beter, The Hague

## BALANCE SHEET AS AT DECEMBER 31, 2022

(1)

(before appropriation of results)

Cash and cash equivalents

Dece	ember 31, 2022	December 31, 2021		
€	€	€	€	

12,120

26,306

**TOTAL ASSETS** 12,120 26,306



December	31, 2022	Decembe	r 31, 2021	
€	€	€	€	

**EQUITY AND LIABILITIES** 

**Capital** (2) 12,120 26,306

**TOTAL LIABILITIES** 12,120 26,306



## 2 PROFIT AND LOSS ACCOUNT OVER 2022

		2022		202	1
		€	€	€	€
<b>Donations</b> Cost of research	(3) (4)	98,865 112,580		28,873 92,500	
Gross margin			-13,715		-63,627
Expenses					
Other operating expenses	(5)		471		415
Result Taxation on result from general			-14,186	-	-64,042
operations				-	
Result			-14,186	=	-64,042



### 3 NOTES TO THE FINANCIAL STATEMENTS

#### Activities

The foundation of Stichting Kind Beter was established by notarial deed on 23 May 2018. The objectives of the Foundation are:

Expanding knowledge with regard to FOXP1 in particular and other related genetic abnormalities. To fund related research and development of gene targeted therapies for FOXP1 and talented syndromes.

### GENERAL PRINCIPLES FOR THE PREPARATION OF THE ANNUAL ACCOUNTS

The annual accounts have been prepared in accordance with Guideline 650 for fundraising institutions of the Dutch Council for Annual Reporting.

The annual accounts have been prepared based on the historical cost. Valuation of assets and liabilities and determination of the result takes place under the historical cost convention.

Income and expenses are allocated to the year to which they relate. Profits are only included insofar as they have been realized on the balance sheet date. Liabilities and possible losses that originate before the end of the reporting year are taken into account if they have become known before the preparation of the annual accounts.

# ACCOUNTING PRINCIPLES APPLIED TO THE VALUATION OF ASSETS AND LIABILITIES

### Cash and cash equivalents

The cash is valued at face value. If cash equivalents are not freely disposable, then this has been taken into account in the valuation.

### PRINCIPLES FOR THE DETERMINATION OF THE RESULT

### General

The result is defined as the difference between the revenue from goods delivered and services performed on one hand and, on the other hand, the costs and expenses for that year, valued at historical costs.

### **Expenses general**

Costs are determined on a historical basis and are attributed to the reporting year to which they relate.



# 4 NOTES TO THE BALANCE SHEET AS OF DECEMBER 31, 2022

## **ASSETS**

	12/31/2022	12/31/2021
	€	€
1. Cash and cash equivalents		
ING Bank N.V.	12,120	26,306

The cash equivalents are at free disposal.



# **EQUITY AND LIABILITIES**

2. Equity

Reconciliation company capital

Consolidated capital 12,120 26,306





## 5 NOTES TO THE PROFIT AND LOSS ACCOUNT 2022

	2022	2021
	€	€
3. Donations		
Donations	98,865	28,873
4. Cost of research		
Contribution to clinical genetics st. LUMC	112,580	92,500
Staff		
During the 2022 financial year the company had no employees.		
5. Other operating expenses		
Sales and distribution expenses	300	300
General expenses	171	115
	<u>471</u>	415
Sales and distribution expenses		
Publicity and advertisement	300	300
General expenses		
Bank charges	171	115